Adlai Nortye Ltd American Depositary Shares (ANL) Stock Price, Quote & News

Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the t...

Industry: Biotechnology

Sector: Healthcare

Phone: 848-230-7430

Website: www.adlainortye.com

Address:

Ugland House, PO Box 309, Grand Cayman, Cayman Islands

Navidas0707 Jun. 25 at 9:15 PM

$ANL

0 · Reply

Navidas0707 Jun. 23 at 5:29 PM

$ANL

0 · Reply

OnlyFibs Jun. 3 at 1:22 AM

RECAP 6/2 +Pos Comments: $ODV + RBC RECAP 6/2 -Neg Comments: $ANL - HC Wainwright

0 · Reply

JarvisFlow Jun. 2 at 4:08 PM

HC Wainwright & Co. has adjusted their stance on Adlai Nortye ( $ANL ), setting the rating to Neutral.

0 · Reply

Beardedd May. 30 at 5:08 PM

$ANL unlikely. Phase 3 failed

0 · Reply

stockmet May. 29 at 3:10 PM

$ANL waking up 📈

0 · Reply

Stmkr May. 7 at 7:17 PM

$ANL leak?

0 · Reply

NextBigRun Apr. 16 at 11:33 PM

UGRO can see a 500% run from here, $4+ Look at the news connected to billion dollar companies today! $PHAT $LOBO $TELO $ANL

0 · Reply

Beardedd Apr. 15 at 2:47 AM

$ANL looks like P3 data now in Q2

0 · Reply

Beardedd Mar. 27 at 11:32 PM

$ANL when Phase 3 data?

0 · Reply

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

May 22, 2024, 8:00 AM EDT - 1 year ago

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Mar 29, 2024, 6:00 AM EDT - 1 year ago

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Nov 17, 2023, 7:30 AM EST - 1 year ago

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Oct 23, 2023, 8:12 AM EDT - 1 year ago

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Oct 13, 2023, 8:00 AM EDT - 1 year ago

Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles

Oct 3, 2023, 12:05 PM EDT - 1 year ago

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Sep 30, 2023, 3:30 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline

BIRK KHIW LRE VSME

Sep 29, 2023, 2:46 AM EDT - 1 year ago

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Sep 3, 2023, 10:45 AM EDT - 1 year ago

U.S. IPO Weekly Recap: August Wraps Up With 1 Nano-Cap

ABNB ARM CART IPO IPOS IVP SNOW

Aug 12, 2023, 6:00 AM EDT - 2 years ago

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices

FTEL NRXS NWGL VFS

Aug 11, 2023, 2:16 PM EDT - 2 years ago

IPO Update: Adlai Nortye Readies $72 Million U.S. IPO

Aug 11, 2023, 7:05 AM EDT - 2 years ago

Cancer treatment company Adlai Nortye sets terms in IPO

Jul 31, 2023, 6:17 PM EDT - 2 years ago

Adlai Nortye Ltd. Begins U.S. IPO Rollout

Navidas0707 Jun. 25 at 9:15 PM

$ANL

0 · Reply

Navidas0707 Jun. 23 at 5:29 PM

$ANL

0 · Reply

OnlyFibs Jun. 3 at 1:22 AM

RECAP 6/2 +Pos Comments: $ODV + RBC RECAP 6/2 -Neg Comments: $ANL - HC Wainwright

0 · Reply

JarvisFlow Jun. 2 at 4:08 PM

HC Wainwright & Co. has adjusted their stance on Adlai Nortye ( $ANL ), setting the rating to Neutral.

0 · Reply

Beardedd May. 30 at 5:08 PM

$ANL unlikely. Phase 3 failed

0 · Reply

stockmet May. 29 at 3:10 PM

$ANL waking up 📈

0 · Reply

Stmkr May. 7 at 7:17 PM

$ANL leak?

0 · Reply

NextBigRun Apr. 16 at 11:33 PM

UGRO can see a 500% run from here, $4+ Look at the news connected to billion dollar companies today! $PHAT $LOBO $TELO $ANL

0 · Reply

Beardedd Apr. 15 at 2:47 AM

$ANL looks like P3 data now in Q2

0 · Reply

Beardedd Mar. 27 at 11:32 PM

$ANL when Phase 3 data?

0 · Reply

PaytiencePaysGreen Mar. 4 at 2:48 PM

$ANL news leaked?

0 · Reply

Stocks771 Feb. 23 at 4:05 PM

$ADIL $ANL $DSS $IPDN $LKCO

0 · Reply

Stmkr Feb. 6 at 4:27 PM

$ANL So when does the run up to the ph3 readout (expected in Q1)start?

0 · Reply

Stmkr Jan. 6 at 8:50 PM

$ANL Ph3 readout expected in Q1. Looks good

0 · Reply

Stmkr Nov. 11 at 2:21 PM

$ANL Probably going down at market open

0 · Reply

Stmkr Nov. 11 at 9:08 AM

$ANL Main catalyst here seems ti be pending ph3 readout expected early 2025 Not too impressive data. Still good TAM and seems to be the most advanced in clinical development

0 · Reply

Stmkr Nov. 11 at 8:28 AM

$ANL Not very impressive. But great proof-of-concept from the single patient that achieved a complete response.

0 · Reply

Iaguy52155 Sep. 5 at 8:03 PM

$ANL stock upgrades n we are 52 week low smfh!

0 · Reply

PurpleSquirrel2020 Sep. 4 at 1:21 PM

$ANL finally getting some play! HC Wainright initiates with $9 Tgt

0 · Reply

Market Cap	60.51M
Revenue (ttm)	0.00
Net Income (ttm)	-51.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.03

Volume	1,600
Avg Vol	19,378
Day's Range	N/A - N/A
Shares Out	36.90M
Stochastic %K	44%
Beta	-0.83
Analysts	Hold
Price Target	$9.00